pharma news today obesity drugs glp-1 today pharma news obesity glp-1 today GLP-1 Agonists Weight Loss Drugs Market Size Report, 2030 GLP-1 Agonists Market Report 2025-2033,
Description
Summary Pulling the new reports together, there is further momentum and excitement building for GLP-1 drug expanded use beyond diabetes and obesity
GLP-1 has a short half-life of only two minutes, due to renal clearance and endogenous GLP-1 is degraded by the enzyme dipeptidyl peptidase IV (DPP-4) (2022)
Although they can have some side effects, such as heartburn, bloating, and rare cases of other more serious digestive diseases, GLP-1s are considered a forever drug in the battle against excess weight
What are GLP-1 drugs and how do they work
Cosmetic Changes: Hair loss
Significantly more tirzepatide patients hit every major weight loss milestone, including 10%, 15%, 20%, and 25% body weight reduction
